Full-Time
Senior Clinical Specialist
Interventional Solutions, Sales
Updated on 9/4/2026
Boston Scientific
10,001+ employees
Medical devices maker for interventional specialties
Compensation Overview
$110k/yr
Minneapolis, MN, USA
Remote
Frequent travel is required; this is a field-based role.
Bachelor's
 Solution Engineering |
|---|
Get referred to Boston Scientific
See people who can refer or advise you
- A bachelor's degree or equivalent work experience is required.
- At least 4 years of experience in medical device sales, healthcare, clinical cardiology, or a related clinical field is required.
- Ability to work flexible hours and travel as required.
- Experience supporting coronary interventions and advanced interventional cardiology technologies, including intravascular imaging and coronary atherectomy.
- Demonstrated success developing customer relationships and expanding product utilization within assigned accounts.
- Experience mentoring or training clinical or commercial team members.
- Strong technical aptitude with the ability to communicate complex clinical and product information.
- Strong business acumen, communication, and problem-solving skills.
- An advanced degree in health care, business, or a related discipline is preferred.
- Execute regional clinical, sales, and service strategies to support market growth and improve customer experience.
- Serve as a primary clinical resource for case coverage, product utilization, troubleshooting, and customer education.
- Provide procedural support during coronary interventions and advise physicians on clinical applications, techniques, and best practices associated with Interventional Solutions products.
- Educate customers on the safe and effective use of company products through presentations, in-services, hands-on training, and procedural support.
- Build and maintain strong relationships with physicians, catheterization laboratory personnel, and key stakeholders within assigned accounts.
- Support product launches and adoption of specialty products through targeted clinical education and training initiatives.
- Identify opportunities to increase product utilization and collaborate with sales partners to execute account growth strategies.
- Assist in the development of physician champions and support engagement with key opinion leaders within the territory.
- Provide guidance and mentorship to newer Clinical Specialists and assist with onboarding and field training activities.
- Support inventory management activities, including consignment inventory tracking, audits, product returns, and expired product management.
- Ensure timely collection and reporting of required procedural and clinical documentation.
- Maintain compliance with company policies, quality standards, and regulatory requirements.
- Experience supporting coronary interventions and advanced interventional cardiology technologies, including intravascular imaging and coronary atherectomy.
- Demonstrated success developing customer relationships and expanding product utilization within assigned accounts.
- Experience mentoring or training clinical or commercial team members.
- Strong technical aptitude with the ability to communicate complex clinical and product information.
- An advanced degree in health care, business, or a related discipline.
Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.
Company Size
10,001+
Company Stage
IPO
Headquarters
Marlborough, Massachusetts
Founded
1979
Get referred to Boston Scientific
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales reached $5.442 billion, up 7.5% reported and 7.0% organically.
- WATCHMAN and electrophysiology remain large franchises despite softer 2026 guidance.
- Penumbra, Valencia Technologies, and Nalu added growth vectors beyond legacy cardiovascular devices.
What critics are saying
- August 25, 2026 cyberattack disrupted global order processing and shipments, with restoration timing unknown.
- September 2, 2026 FDA Class 2 LUX-Dx recall exposed delayed AF alerts in LATITUDE Clarity.
- If cyber outages persist into Q3 2026, hospitals will switch orders to Medtronic and Abbott.
What makes Boston Scientific unique
- Boston Scientific spans cardiology, endoscopy, urology, and neuromodulation across 127 countries.
- January 2026 Penumbra acquisition broadened its neurovascular and peripheral thrombectomy portfolio.
- March 2026 Asurys clearance expands its urology platform for endoscopic procedures.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Relocation Assistance
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 12%Heart monitor server software used by Boston Scientific patients draws three Class 2 recalls over delayed alerts. Published Sep 03, 2026 3:40 PM EDT By Joseph James Federal regulators posted three Class 2 recall records on Wednesday covering the server software behind Boston Scientific's LUX-Dx family of implanted heart monitors, after the company identified a flaw that can delay alerts about atrial fibrillation. The implanted devices themselves are working as designed, and Boston Scientific is not recommending that anyone have a monitor removed. The distinction between the implant and the software that receives its data is the whole story here, and it is the part most likely to alarm patients unnecessarily. LUX-Dx monitors are small devices placed under the skin to watch continuously for abnormal heart rhythms. They continue to detect atrial fibrillation, store the data, and transmit it. What can be delayed is one specific notification that reaches the clinical team through the LATITUDE Clarity server. Atrial fibrillation is the most common sustained heart rhythm disorder, and untreated episodes raise stroke risk substantially. That is why the timing of an alert matters even when the hardware is functioning. The configuration that triggers the problem. According to the FDA recall record covering the United States software, listed as recall number Z-3081-2026, the delay occurs only when the AF Burden Alert threshold is configured to greater than zero hours per day. That is a non-default setting, which means most patients are not affected by it. When the threshold is set that way, notification of an AF Burden Alert may be delayed, which in turn may delay clinical evaluation or therapeutic intervention for an atrial arrhythmia. The FDA attributed the cause to software design. Boston Scientific has received one complaint related to the behavior. No patient injuries or deaths have been reported. The company sent an Urgent Medical Device Correction to customers in August and says a server software update is planned to fix it. The recall records remain open, meaning the correction is not yet complete across all affected products. The company initiated the action on August 6, and the FDA posted the classification records on September 2. The gap between company action and public posting is routine for device recalls, since the agency classifies severity after the firm reports the correction. Insertable cardiac monitors are typically implanted in patients being evaluated for unexplained fainting, palpitations, or suspected atrial fibrillation, and in stroke survivors whose stroke had no identified cause. In that last group especially, catching an arrhythmia can determine whether a patient is started on an anticoagulant. Three records for one problem. A detail worth flagging for anyone tracking this: the FDA created three separate recall records under a single recall event identified as 99524, one for each regional version of the server software. Z-3081-2026 covers the United States version, model number 7260, at a current version of 7.8. Z-3082-2026 covers the European version, model 7246, and Z-3083-2026 covers the Australia and New Zealand version, model 7248, both at a current version of 7.7. All three carry the same reason for recall, the same FDA determined cause and the same September 2 posting date. All three are Class 2, the middle severity tier the FDA uses when a product may cause temporary or medically reversible harm. Distribution is listed as worldwide, with nationwide distribution in the United States. The records do not specify how many patients or facilities are affected. Interim steps that belong to clinicians, not patients. Boston Scientific outlined two options for managing the issue until the software update arrives, and both are settings changes made by the clinical team rather than anything a patient can do. Clinics can change the threshold for the AF Burden Alert setting, or they can enable the AF Events Alert with a minimum duration. The LATITUDE Clarity system detects atrial fibrillation through two independent mechanisms, AF Burden and AF Event alerts, so configuring the second one provides a workaround while the first is affected. The company asked customers to share the notification with all clinicians in their organization who manage patients using LUX-Dx monitors and the LATITUDE Clarity system. Boston Scientific also noted that regulatory authorities in affected countries were informed, and that adverse events should be reported through standard channels. For patients, the practical action is limited and specific. Anyone with a LUX-Dx, LUX-Dx II or LUX-Dx II+ monitor can contact their cardiology or electrophysiology clinic to ask whether their alert settings use the affected configuration and whether the clinic has applied one of the interim options. Nobody should stop transmitting data, skip a scheduled follow-up, or consider removal. The FDA explains what a device recall means and notes that many recalls involve corrections rather than product removal, which is the case here. Symptoms that warrant attention regardless of alerts. Remote monitoring is a supplement to symptom awareness, not a replacement for it, and this recall is a reminder of why that distinction matters. Atrial fibrillation can produce a fluttering or racing heartbeat, an irregular pulse, shortness of breath, fatigue, reduced exercise tolerance, dizziness, or chest discomfort. Some people feel nothing at all, which is precisely the reason these monitors exist and why a delayed alert is worth taking seriously even in the absence of reported harm. Anyone experiencing chest pain, severe shortness of breath, fainting or signs of stroke including sudden face drooping, arm weakness or speech difficulty should call 911 rather than wait for a device notification. People taking anticoagulants for atrial fibrillation should continue them as prescribed. No one should change a medication based on a device recall. Boston Scientific has not published a date for the server software update. The FDA recall records will be updated as the status changes and will show as terminated once the correction is complete. Key questions answered. Does this recall mean the implanted device must be removed? No. Boston Scientific explicitly does not recommend replacement of the implanted monitor. The recall covers server software, and the implant continues to detect, store, and transmit data as intended. What exactly can go wrong? Notification of an AF Burden Alert may be delayed, which could delay clinical evaluation or treatment of an atrial arrhythmia. It occurs only when the alert threshold is set to a non-default configuration. Has anyone been harmed? Boston Scientific reported one complaint about the delayed notification behavior. No patient injuries or deaths have been reported in the FDA records. What does Class 2 mean? Class 2 is the FDA's middle severity classification, used when a product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm. Which products are covered? Server software supporting the LUX-Dx, LUX-Dx II and LUX-Dx II+ Insertable Cardiac Monitor System. Three records cover the United States, European, and Australia and New Zealand versions under one recall event. What should a patient with one of these monitors do? Contact the cardiology or electrophysiology clinic to ask about alert settings and whether an interim configuration has been applied. Continue transmissions, follow-ups, and prescribed medications. When will the software be fixed? Boston Scientific says a server software update is planned but has not published a date. The FDA records remain open until the correction is complete. Published by Medicaldaily.com
Boston Scientific cyberattack disrupts manufacturing and product shipments. September 1, 2026 Boston Scientific is working to restore its manufacturing, order processing, and distribution capabilities following a cybersecurity incident that caused a network outage across certain internal IT systems. Discover more Securing Personal Computers Exploring Online Dictionaries Computer Security In an August 30 update, the medical device manufacturer reported that investigators had found no signs of unauthorized activity in its environment since August 25. The disruption is limited to specific on-premises systems; cloud-based systems and applications remain unaffected. The company has engaged CrowdStrike and other third-party cybersecurity experts to assist with ongoing investigation and recovery efforts. Boston Scientific cyberattack. Boston Scientific first disclosed the incident on August 26, indicating that it had identified the issue a day earlier and activated incident response protocols to investigate and contain the threat. The outage has disrupted access to the operating systems and business applications necessary to manufacture products, process customer orders, and ship finished devices. Customers can still submit orders electronically through electronic data interchange (EDI) and local applications; however, these orders are currently held in a fulfillment queue until the affected operations resume. The company aims to partially restore shipping capabilities this week, with a plan to gradually ramp up order processing and shipping to full capacity once the environment is operational again. The operational disruption has direct clinical implications, as Boston Scientific provides medical technologies and manages connected device services. The company confirmed that there has been no known impact on devices not connected to the Boston Scientific network, nor is there any evidence that the affected systems have increased cybersecurity risks for hospital networks using its devices. It also reported no known issues with the functionality of implantable cardiac rhythm management devices, programmer interrogations, or remote monitoring for devices already enrolled before the outage. However, new remote monitoring activations are currently affected, delaying communications and data transmission for some newly implanted cardiac devices and insertable cardiac monitors. For non-ICM CRM implants, new remote monitoring communicators cannot be activated at this time, meaning that the available device data will not reach remote patient management systems until activation resumes. For new ICM implants, the Clinic Assistant app can activate recording. However, the affected devices cannot pair with the patient's remote monitoring mobile phone. Discover more Installing Security Systems Learning Computer Science Boston Scientific reported that episodes continue to be recorded and can be transmitted via the app during in-person interrogations. Once pairing and systems are restored, stored data should be sent to the remote monitoring platform. The company has not yet provided a timeline for complete restoration. Recovery now depends on safely rebuilding access to core on-premises business processes without compromising medical product availability or patient care. This incident highlights how IT outages at healthcare manufacturers can extend beyond corporate workflows into production, logistics, and connected care onboarding. Boston Scientific stated it is prioritizing systems that have the greatest impact on customers and product delivery and will issue further updates as functionality is restored. The company's newsroom has publicly posted updates on the incident for stakeholders. Prevent incidents due to slow investigations. Power your Tier 1 with threat intelligence from 15K SOCs: Integrate TI Lookup in your SOC Divya is a Senior Journalist at GBhackers covering Cyber Attacks, Threats, Breaches, Vulnerabilities and other happenings in the cyber world. Hot this week
Healthcare cyberattacks hit pacemakers and millions of patient records. McKesson admits breach as ShinyHunters demands $55.2M Published Mon 31 Aug 2026 // 22:10 UTC Two major healthcare businesses, Boston Scientific and McKesson, disclosed more details over the weekend about separate cyberattacks that disrupted global operations and resulted in stolen patient data, respectively. Medical-device maker Boston Scientific, whose IT systems were hacked by unknown intruders last week, said the cyberattack remains ongoing. It also noted that pacemakers and other heart devices implanted after the August 25 breach cannot provide remote monitoring and data transmission as intended. "New remote monitoring communicators cannot be activated, thus available device data will NOT be transmitted to remote patient management systems until the communicator can be activated," the medtech firm said in a late Friday update. This applies to all new cardiac rhythm management implants other than insertable cardiac monitors (ICM). ICM devices must be activated using the Boston Scientific Clinic Assistant app to ensure the device correctly records patients' heart rhythms, the company added. Because of the cyberattack, "new ICMs are unable to pair to the patient remote monitoring mobile phone, therefore available episode data recorded by the ICM will NOT be transmitted to the remote monitoring system until the ICM can be paired to the patient mobile app," according to the update. The devices will still record any episodes, and patients can transmit these to the remote monitoring system by in-person transmission via the Clinic Assistant app. This is done by selecting the "interrogate" button, according to the company. Once its IT systems are back up and running, and the heart devices can pair with home monitoring equipment, they will again transmit recorded data to the remote systems. However, the company does not have a timeline for full restoration. "We are currently working on restoring affected functions and systems access," Boston Scientific said on Saturday. The digital intrusion also affected the firm's manufacturing, shipping, and ordering, it noted. "We are expeditiously working towards partial restoration for the shipping of some products this week," according to a Sunday update. "Once we can demonstrate the restoration is fully operable, we anticipate ordering and shipping will ramp up to full capacity." Boston Scientific has hired CrowdStrike to assist with the investigation and restoration efforts, and said the attack did not affect its cloud-based systems and apps - just "certain on-premise systems" - and added that it has seen no indication of unauthorized IT activity since August 25. The firm has repeatedly declined to answer The Register's questions about the compromise, including whether it was a ransomware infection and which criminal crew is responsible. McKesson confirms breach as ShinyHunters claims responsibility. Meanwhile, in another cybersecurity incident that has been very publicly claimed by the criminal perpetrator: pharmaceutical and medical supply giant McKesson over the weekend confirmed an intrusion after ShinyHunters on Friday told The Register it broke into the company's Snowflake and Salesforce instances and stole millions of patients' data. "Based on our investigation thus far, including assessments by leading cybersecurity industry experts supporting our response, we've confirmed that the unauthorized access to certain third-party applications and the exfiltration of certain data was associated with a subset of customers within our Oncology & Multispecialty and Medical-Surgical business units," Francisco Fraga, McKesson executive VP, chief information officer and chief technology officer, said in a Saturday statement. The medical firm did not immediately respond to The Register's questions, including how many patients were affected and what "certain data" was stolen. McKesson supports about 3,300 oncology providers in 29 states, according to its website. Fraga's statement noted that distribution centers remain operational and McKesson continues to ship products. The firm has "reasonable assurance" that the digital intruders have been kicked out of the third-party environments and aren't lurking around McKesson's systems, he added. A ShinyHunters spokesperson told Hypriot that the notorious extortion group compromised more than 284 million records of patient data, and demanded McKesson pay $55.2 million or else they would leak the stolen data. However, as Have I Been Pwned boss Troy Hunt recently reminded everyone: Don't confuse criminals' claims with gospel truth, and "take headline numbers with a grain of salt unless you're confident in the processes of those making the claims." This was after Hunt's HIBP service reported 12.9 million individuals affected by retailer Carhartt's alleged breach. This number was around half of what ShinyHunters claimed when they leaked the company's data earlier this month. The McKesson records, according to the ShinyHunters spokesperson, include patients' full names, home and email addresses, phone numbers, dates of birth, Social Security numbers, appointment dates and notes, and sensitive illness details including cancer locations on people's bodies. The group also claims to have swiped emails containing private information from doctors to patients. The spokesperson told Hypriot they accessed the company's Snowflake and Salesforce instances by voice phishing "multiple employees." This is a tried-and-true method popularized by the data-theft-and-extortion gang, which has victimized other medical providers in recent months. These include pacemaker manufacturer Medtronic in April, and cancer diagnostics business Exact Sciences in July.(R)
COGNOSCERE Daily Tech Review - Issue T222 · Saturday, August 29, 2026. Curated by COGNOSCERE Editorial Team · Daily Tech Review · August 29, 2026 Saturday, August 29, 2026 · Issue #T222 | 7 ARTICLES | 1 ACT | 1 PREPARE | Information Technology · 4 articles. Ubiquiti released Security Advisory Bulletin 067 patching 22 vulnerabilities across its UniFi product line, including three CVSS 10.0 flaws enabling unauthenticated command injection and authentication bypass across UniFi Protect (camera surveillance), UniFi Talk (VoIP), and UniFi OS (network management). No active exploitation has been confirmed, but prior Ubiquiti CVSS 10 flaws were weaponized within days of disclosure. CyberScoop · Cybersecurity / Network Security · Relevance: 0.9 · Source vulnerability, network security, Ubiquiti, UniFi, patch, authentication bypass, command injection, enterprise networking Boston Scientific disclosed via an SEC 8-K filing that a cyberattack detected August 25 is causing a global disruption to its operations, impairing its ability to process and ship customer orders for medical devices including pacemakers and defibrillators across 127 countries. The company engaged third-party cybersecurity experts; the attacker, attack type, and data impact remain undisclosed. TechCrunch · Cybersecurity / Incident Response · Relevance: 0.9 · Source cyberattack, healthcare, medical devices, supply chain disruption, SEC disclosure, incident response, OT security AWS announced it will deploy an additional 2 million Nvidia GPUs - including Blackwell Ultra, Rubin, and Rubin Ultra systems - in 2027-2028, tripling a prior commitment of over 1 million chips, and expanding collaboration to include Nvidia Vera CPUs, Nemotron open models on Bedrock and SageMaker, and joint AI factory builds for the US government. TechCrunch · Cloud Computing / AI Infrastructure · Relevance: 0.9 · Source cloud infrastructure, GPU, AI hardware, AWS, Nvidia, data center expansion, AI factories, government AI Meta settled a landmark multi-state federal lawsuit alleging its platforms harmed young users, agreeing to pay up to $18 billion and implement sweeping changes to Facebook and Instagram for users under 18 - including a default 2-hour daily limit, midnight-to-6am lockout, and tighter age verification. About $5.3 billion of the settlement is contingent on TikTok and YouTube adopting comparable restrictions and paying equivalent sums. CNN · Regulation / Platform Policy · Relevance: 0.8 · Source Artificial Intelligence · 2 articles. Chinese AI lab Z.AI (Zhipu AI) confirmed that Ox Alpha - the anonymous model that led OpenRouter's leaderboards for a week - is GLM-5.3-Flash, a 320B-parameter MoE model with 18B active parameters, native multimodality, and a 1M-token context window, now released under an MIT license at roughly one-tenth the cost of comparable frontier models. The entire preview period was served on Chinese-made AI chips, raising competitive significance in the AI infrastructure supply chain. SiliconANGLE · AI Model Releases / Open Source AI · Relevance: 0.9 · Source open-source AI, model release, China AI, MoE, multimodal, cost efficiency, Chinese chips, AI competition Barret Zoph, a co-founder of Thinking Machines Lab who had recently joined OpenAI following a leadership dispute, is leaving OpenAI to become Google's Vice President of Research. The move arrives as Google restructures its AI development efforts to accelerate AI coding capabilities and compete with rivals. TLDR AI · AI Leadership / Executive Moves · Relevance: 0.8 · Source executive move, AI talent, Google, OpenAI, AI research, AI leadership Decision Support · 1 article. Dun & Bradstreet is integrating its D&B Commercial Graph and risk analytics into Perplexity and its Computer agent platform via Model Context Protocol servers, giving business users direct access to verified company identities, ownership relationships, and risk intelligence for workflows including KYC/KYB, procurement, finance, compliance, and sales - without leaving the AI interface. Digital IT News · Business Intelligence / Risk Analytics · Relevance: 0.8 · Source business intelligence, risk analytics, KYC, KYB, MCP, agentic AI, compliance, decision support, data integration Entity watch (7-day). | Entity | Type | Mentions | Active | Domains | | Nvidia | company | 11 | 5d | AI,IT | | OpenAI | company | 10 | 6d | AI,IT | | Anthropic | company | 10 | 5d | AI,DS,IT | | Microsoft | company | 9 | 6d | AI,IT | | Hugging Face | company | 5 | 4d | AI,IT | | Claude | product | 5 | 4d | AI,DS | | Amazon Web Services | company | 5 | 4d | AI,DS,IT | | Google | company | 5 | 3d | AI,IT | | Ox Alpha | product | 4 | 4d | AI | | OpenRouter | company | 4 | 4d | AI | Domain pulse (7-day). Artificial Intelligence 27 articles · Avg relevance: 0.87 · ACT: 4 · PREPARE: 4 Decision Support 10 articles · Avg relevance: 0.81 · ACT: 0 · PREPARE: 4 Information Technology 40 articles · Avg relevance: 0.86 · ACT: 10 · PREPARE: 13 | | BEYOND THE BRIEF | COGNOSCERE | Intelligence is leverage - but only when you act on it. CIFaaS turns the signals in today's brief into tracked, attributable decisions for your business. Sources preserved. Reasoning shown. Audit trail intact. Free to start · No card required · 60-second signup or engage COGNOSCERE directly | [01] ADVISORY Decision support for boards, leadership, and ops teams. Services | | [02] LIBRARY Past briefs and the CIF intelligence archive. Intelligence | | [03] NEWSLETTERS Add to your morning inbox. News pre-selected, Tech optional. Subscribe | | COGNOSCERE Daily Tech Review · Issue #T222 · Saturday, August 29, 2026
Capital Medical Center makes regional history with innovative vascular technology. The Pulse Vascular Team at Capital Medical Center has achieved a remarkable milestone, becoming the first hospital in the Pacific Northwest to use Boston Scientific's newly released Intravascular Lithotripsy (IVL) Device. This groundbreaking achievement places Capital Medical Center at the forefront of vascular innovation across Washington, Oregon, Idaho, Montana, and Alaska. The team successfully used the device in two procedures, one performed by Dr. Wasilenko and the other by Dr. Hillenbrand, with excellent clinical results in both cases. The new Intravascular Lithotripsy technology is designed to help physicians treat heavily calcified blood vessels, making procedures more effective and expanding treatment options for patients with complex vascular disease. Being selected as the first hospital in the region to utilize this advanced technology reflects the expertise, preparation, and commitment to excellence demonstrated by the entire Pulse Vascular Team. The successful introduction of the device required close collaboration among physicians, nurses, technologists, and support staff, highlighting the strength of Capital Medical Center's multidisciplinary approach to patient care. As Capital Medical Center continues to invest in leading-edge treatments and technologies, achievements like this reinforce the organization's commitment to providing patients with access to innovative care close to home. Congratulations to Dr. Wasilenko, Dr. Hillenbrand, and the entire Pulse Vascular Team for this pioneering accomplishment and for continuing to raise the standard of vascular care in its region. Inland Northwest 509-755-5500 Puget Sound Region 253-572-7320